# GALR1

## Overview
The GALR1 gene encodes the galanin receptor 1, a member of the G-protein-coupled receptor (GPCR) family, which plays a crucial role in various physiological processes. This receptor is characterized by its seven transmembrane domains, typical of GPCRs, and is involved in signal transduction by interacting with Gi-type G-proteins (LANG2007The; HabertOrtoli1994Molecular). The GALR1 protein is implicated in modulating neurotransmission, pain perception, and anxiety-related behaviors, as well as in regulating gastrointestinal functions and glucose homeostasis (Gopalakrishnan2020An; LANG2007The). Additionally, GALR1 forms heteroreceptor complexes with other receptors, influencing various signaling pathways and contributing to its diverse physiological roles (BorrotoEscuela2010Galanin; Fuxe2012On). Alterations in GALR1 expression and function have been linked to several diseases, including cancer and neurological disorders, underscoring its clinical significance (Kanazawa2019Promoter; Misawa2008Epigenetic).

## Structure
The GALR1 protein is a G-protein-coupled receptor (GPCR) consisting of 349 amino acids with a predicted molecular mass of 38.9 kDa (HabertOrtoli1994Molecular). Its primary structure includes a single open reading frame of 1053 base pairs (HabertOrtoli1994Molecular). The secondary structure is characterized by seven hydrophobic transmembrane domains, typical of GPCRs, with an extracellular N-terminus and a cytoplasmic C-terminus (HabertOrtoli1994Molecular). 

The tertiary structure of GALR1 includes features such as a pair of cysteine residues likely forming a disulfide bond in the first and second extracellular loops, and proline residues in the fourth, fifth, and seventh transmembrane domains, which may introduce bends in the alpha-helical structure (HabertOrtoli1994Molecular). The protein also has potential phosphorylation sites in the cytoplasmic domain and consensus N-glycosylation sites in the N-terminal region (HabertOrtoli1994Molecular). The C-terminal region may attach to the membrane via a farnesyl anchor (HabertOrtoli1994Molecular). 

The quaternary structure is not explicitly detailed, but the receptor's ability to bind galanin and transduce signals suggests functional oligomerization typical of GPCRs (HabertOrtoli1994Molecular).

## Function
GALR1 (galanin receptor 1) is a G-protein-coupled receptor involved in various molecular processes in healthy human cells. It primarily functions by inhibiting adenylyl cyclase activity, leading to reduced cAMP production, and is associated with the opening of G-protein-regulated inwardly rectifying K+ channels and stimulation of mitogen-activated protein kinase (MAPK) activity (LANG2007The). GALR1 is linked to Gi-type G-proteins, which mediate these effects through Gαi-subunits and Gβγ-subunits (LANG2007The).

In the gastrointestinal tract, GALR1 is expressed in the human colon and epithelial cells, where it regulates peristalsis and chloride secretion. Its expression is upregulated during inflammatory processes, suggesting a role in gastrointestinal inflammation (LANG2007The). GALR1 also plays a role in insulin resistance amelioration by facilitating adiponectin release and promoting glucose transporter GLUT4 translocation, which is crucial for glucose homeostasis (Gopalakrishnan2020An).

In the central nervous system, GALR1 is involved in modulating pain perception and anxiety-related behaviors. It exerts anxiolytic effects and is implicated in the analgesic effects of galanin during acute pain (LANG2007The). GALR1's activity in these processes highlights its importance in maintaining physiological balance and responding to stressors in the body.

## Clinical Significance
Alterations in the expression and function of the GALR1 gene have been implicated in several diseases, particularly in the context of cancer and neurological disorders. In head and neck squamous cell carcinoma (HNSCC), GALR1 is frequently inactivated due to promoter hypermethylation, which silences the gene and is associated with increased tumor size, lymph node involvement, and decreased survival rates. This epigenetic silencing suggests that GALR1 acts as a tumor suppressor gene, and its inactivation contributes to aggressive tumor progression (Kanazawa2019Promoter; Misawa2008Epigenetic). The methylation status of GALR1 is also linked to poor prognosis in salivary duct carcinoma and other cancers, making it a potential biomarker for predicting clinical outcomes (Sánchez2022The; Kanazawa2019Promoter).

In neurological conditions, GALR1 has been associated with epilepsy. Studies in mice have shown that the knockout of GALR1 leads to spontaneous epilepsy and abnormal EEGs, indicating its role in maintaining normal neuronal inhibition. The absence of GALR1 results in increased seizure susceptibility, highlighting its importance in neurological health (McColl2006Galanin).

## Interactions
GALR1, a G protein-coupled receptor, is known to form heteroreceptor complexes with other receptors, influencing various signaling pathways. One significant interaction is with the 5-hydroxytryptamine-1A (5-HT1A) receptor, where GALR1 forms heterodimers that exhibit antagonistic allosteric interactions. This interaction modulates signaling pathways by preventing excessive activation of Gi/o proteins, which can inhibit adenylyl cyclase and affect MAPK activity (BorrotoEscuela2010Galanin; Fuxe2012On).

GALR1 also interacts with GalR2 to form heteroreceptor complexes that are implicated in depression. These complexes can lead to increased Gi/o mediated signaling, contributing to depressive effects (BorrotoEscuela2017Understanding; Gopalakrishnan2020An). The potential formation of a trimeric complex involving GALR1, GalR2, and 5-HT1A receptors has been suggested, which may enhance antidepressant effects through novel allosteric interactions (BorrotoEscuela2017Understanding).

In the context of cardiovascular regulation, GALR1 is proposed to form heterotrimers with GalR2 and NPYY2 receptors in the nucleus tractus solitarius, influencing vasopressor activity through specific receptor-receptor interactions (Fuxe2012On). These interactions highlight the role of GALR1 in modulating complex physiological processes through its ability to form diverse receptor complexes.


## References


[1. (BorrotoEscuela2010Galanin) Dasiel O. Borroto-Escuela, Manuel Narvaez, Daniel Marcellino, Concepción Parrado, José Angel Narvaez, Alexander O. Tarakanov, Luigi F. Agnati, Zaida Díaz-Cabiale, and Kjell Fuxe. Galanin receptor-1 modulates 5-hydroxtryptamine-1a signaling via heterodimerization. Biochemical and Biophysical Research Communications, 393(4):767–772, March 2010. URL: http://dx.doi.org/10.1016/j.bbrc.2010.02.078, doi:10.1016/j.bbrc.2010.02.078. This article has 74 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2010.02.078)

[2. (Misawa2008Epigenetic) Kiyoshi Misawa, Yo Ueda, Takeharu Kanazawa, Yuki Misawa, Ilwhan Jang, John Chadwick Brenner, Tetsuya Ogawa, Satoru Takebayashi, Reidar A. Grenman, James G. Herman, Hiroyuki Mineta, and Thomas E. Carey. Epigenetic inactivation of galanin receptor 1 in head and neck cancer. Clinical Cancer Research, 14(23):7604–7613, December 2008. URL: http://dx.doi.org/10.1158/1078-0432.ccr-07-4673, doi:10.1158/1078-0432.ccr-07-4673. This article has 53 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1158/1078-0432.ccr-07-4673)

[3. (McColl2006Galanin) Craig D. McColl, Arie S. Jacoby, John Shine, Tiina P. Iismaa, and John M. Bekkers. Galanin receptor-1 knockout mice exhibit spontaneous epilepsy, abnormal eegs and altered inhibition in the hippocampus. Neuropharmacology, 50(2):209–218, February 2006. URL: http://dx.doi.org/10.1016/j.neuropharm.2005.09.001, doi:10.1016/j.neuropharm.2005.09.001. This article has 26 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.neuropharm.2005.09.001)

[4. (Fuxe2012On) Kjell Fuxe, Dasiel O. Borroto-Escuela, Wilber Romero-Fernandez, Alexander O. Tarakanov, Feliciano Calvo, Pere Garriga, Mercé Tena, Manuel Narvaez, Carmelo Millón, Concepción Parrado, Francisco Ciruela, Luigi F. Agnati, José A. Narvaez, and Zaida Díaz-Cabiale. On the existence and function of galanin receptor heteromers in the central nervous system. Frontiers in Endocrinology, 2012. URL: http://dx.doi.org/10.3389/fendo.2012.00127, doi:10.3389/fendo.2012.00127. This article has 55 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2012.00127)

[5. (Sánchez2022The) Manuel Lisardo Sánchez and Rafael Coveñas. The galaninergic system: a target for cancer treatment. Cancers, 14(15):3755, August 2022. URL: http://dx.doi.org/10.3390/cancers14153755, doi:10.3390/cancers14153755. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers14153755)

[6. (HabertOrtoli1994Molecular) E Habert-Ortoli, B Amiranoff, I Loquet, M Laburthe, and J F Mayaux. Molecular cloning of a functional human galanin receptor. Proceedings of the National Academy of Sciences, 91(21):9780–9783, October 1994. URL: http://dx.doi.org/10.1073/pnas.91.21.9780, doi:10.1073/pnas.91.21.9780. This article has 278 citations.](https://doi.org/10.1073/pnas.91.21.9780)

[7. (BorrotoEscuela2017Understanding) Dasiel O. Borroto-Escuela, Jens Carlsson, Patricia Ambrogini, Manuel Narváez, Karolina Wydra, Alexander O. Tarakanov, Xiang Li, Carmelo Millón, Luca Ferraro, Riccardo Cuppini, Sergio Tanganelli, Fang Liu, Malgorzata Filip, Zaida Diaz-Cabiale, and Kjell Fuxe. Understanding the role of gpcr heteroreceptor complexes in modulating the brain networks in health and disease. Frontiers in Cellular Neuroscience, February 2017. URL: http://dx.doi.org/10.3389/fncel.2017.00037, doi:10.3389/fncel.2017.00037. This article has 87 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fncel.2017.00037)

[8. (Gopalakrishnan2020An) Lathika Gopalakrishnan, Oishi Chatterjee, Chinmayi Raj, Deepshika Pullimamidi, Jayshree Advani, Anita Mahadevan, and T. S. Keshava Prasad. An assembly of galanin–galanin receptor signaling network. Journal of Cell Communication and Signaling, 15(2):269–275, November 2020. URL: http://dx.doi.org/10.1007/s12079-020-00590-3, doi:10.1007/s12079-020-00590-3. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12079-020-00590-3)

[9. (LANG2007The) R LANG, A GUNDLACH, and B KOFLER. The galanin peptide family: receptor pharmacology, pleiotropic biological actions, and implications in health and disease. Pharmacology &amp; Therapeutics, 115(2):177–207, August 2007. URL: http://dx.doi.org/10.1016/j.pharmthera.2007.05.009, doi:10.1016/j.pharmthera.2007.05.009. This article has 302 citations.](https://doi.org/10.1016/j.pharmthera.2007.05.009)

[10. (Kanazawa2019Promoter) Takeharu Kanazawa, Kiyoshi Misawa, Kazuya Shinmura, Yuki Misawa, Gen Kusaka, Mikiko Maruta, Toru Sasaki, Yusuke Watanabe, and Thomas E. Carey. Promoter methylation of galanin receptors as epigenetic biomarkers for head and neck squamous cell carcinomas. Expert Review of Molecular Diagnostics, 19(2):137–148, January 2019. URL: http://dx.doi.org/10.1080/14737159.2019.1567334, doi:10.1080/14737159.2019.1567334. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/14737159.2019.1567334)